To read the full story, subscribe or sign in.

Gilead Buying Rest Of Corus; $365M Plus Lawsuit Payout

July 21, 2006

Just more than three months after pumping $25 million into Corus Pharma Inc., Gilead Sciences Inc. - already Corus' largest shareholder - is exercising its option to buy out the firm, at a price tag of $365 million. (BioWorld Today)

BioWorld

Today's news in brief

BioWorld

BioWorld briefs for March 4, 2026.

CROI 2026: Neurodegeneration, the challenge of aging with HIV

BioWorld

Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...

News in brief

BioWorld Asia

BioWorld Asia briefs for March 3, 2026

Depression concept with human, broken brain and heavy rain

CROI 2026 highlights depression and cognitive vulnerability in HIV

BioWorld

The effects of aging pose an additional challenge for people with HIV due to the neurological and psychological consequences that persist despite antiretroviral...

Slate Medicines launches with focus on headache disorders

BioWorld Science

Slate Medicines Inc. has launched with $130 million in series A financing and a focus on advancing next-generation therapeutics for migraine and other headache...